lessthanhalf said:
Whatever people put in their stacks is pure invention. When it comes to combining or sequencing these peptides, there is no scientific literature at all.
SS-31 holds approval for Barth syndrome, a genetic mitochondrial disorder. It has gone through a handful of human trials for other indications, yet those results were mostly underwhelming, and development for broader uses was largely abandoned. Outside of animal work, I know of no ongoing drug programs for it beyond Barth syndrome.
Mots-c, or CB4211, a close relative, has completed 1 phase 1 trial and is expected to enter a phase 2 trial for fatty liver disease. That covers the entire human trial record.
For each peptide, there are assorted mouse and cell studies with intriguing findings. Still, fewer than 1 in 10 promising drugs succeed in human clinical trials, so assuming cell or animal results will translate to people is neither safe nor reasonable, given that less than 1 in 10 figure. To my knowledge, no cell or animal data supports using them together or in sequence either.
At some point, someone clearly dreamed up a rationale for that sequence, and it makes a compelling tale for selling peptides, but it carries no scientific weight.
Both peptides do produce genuine biological effects. SS-31, I believe, has been tested enough to show it fails at the hoped-for goals, such as treating heart failure, though it caused no harm in those trials.
Mots-c sounds even more promising, behaving like exercise in a pill for mice, but 1 phase 1 study on liver disease does not remotely establish human safety or the same metabolic advantages seen in mice. There is a slim possibility it will one day be proven safe and effective, but many hurdles remain, and a drug company would need to judge it worthy of millions in trial spending. One company apparently thinks so for fatty liver and is pursuing development, yet even those trials will not demonstrate benefits for other conditions.
